Product news

Share this article:
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals announced that the FDA has approved a supplemental New Drug Application for Nexavar (sorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma, or liver cancer. Nexavar, an oral anticancer drug, is the first approved systemic therapy for liver cancer and the only one shown to significantly improve overall survival in patients with the disease.
 
Wyeth, announced that the FDA has approved Protonix (pantoprazole sodium) delayed-release oral suspension, providing adult patients who cannot swallow tablets with an effective and convenient way to treat their erosive gastroesophageal reflux disease.
 
AstraZeneca said the FDA has approved once-daily Seroquel XR (quetiapine fumarate) extended-release tablets for maintenance treatment of schizophrenia in adult patients.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions